BrainTransporter™ significantly enhances brain antibody delivery

STOCKHOLM, Nov. 6, 2024 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) has introduced the design of its innovative BrainTransporter (BT) platform during the 16th annual Protein & Antibody Engineering Summit (PEGS) conference in Barcelona, Spain. This BT platform leverages Transferrin Receptor (TfR)-mediated transport, allowing significantly higher antibody penetration through the blood-brain barrier (BBB) without adversely affecting hematological safety parameters.

At the PEGS Europe conference, Dr. Per-Ola Freskgård, VP Science & Technology at BioArctic, unveiled the BT platform and showcased preclinical model validations. He highlighted the challenges in brain uptake of biotherapeutics like antibodies and enzymes, primarily hindered by the BBB due to their molecular size. The BT platform aims to enhance drug delivery into the brain by using TfR, a protein that aids in transporting substances across the BBB.

The presentation showcased preclinical outcomes that revealed up to a 70-fold increase in amyloid-beta antibody brain exposure using the BT technology. This included rapid, extensive distribution of these antibodies throughout the brain, thereby validating the efficacy of a BT-linked amyloid-beta monoclonal antibody in preclinical models without negative impacts on hematological parameters such as reticulocytes.

Gunilla Osswald, CEO at BioArctic, expressed her excitement about the promising preclinical data, emphasizing that the BrainTransporter technology has substantial potential in enhancing various therapies. By facilitating greater drug delivery to brain targets, this technology could revolutionize treatments for various brain disorders, offering patients new therapeutic options with fewer side effects and lower dosages, benefiting both patients and society.

The BT technology offers potential applications across multiple therapeutic areas, presenting numerous future partnering opportunities for BioArctic. In April 2024, BioArctic AB and Eisai Co., Ltd., entered into their first agreement involving the BT-technology, focusing on BAN2802, a prospective treatment that integrates BioArctic's BrainTransporter technology with an unnamed Alzheimer drug candidate.

About BioArctic:
BioArctic AB (publ) is a Swedish biopharmaceutical company dedicated to developing treatments to slow or halt the progression of neurodegenerative diseases. Notably, the company developed Leqembi® (lecanemab), the first drug proven to decelerate disease progression and diminish cognitive decline in early Alzheimer's patients. In collaboration with Eisai, BioArctic has a diverse research portfolio targeting Parkinson's disease, ALS, and other Alzheimer’s disease projects, many of which utilize the company's proprietary BrainTransporter™ technology to enhance treatment efficacy by improving antibody transport across the blood-brain barrier. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap.

For additional information, please visit BioArctic's website.